Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14977060 | 0.85 | GDA (0.33) | PDPK1BTKGAAGDAKDM4E | |
| SCHEMBL10047091 | 0.82 | CDK1 (0.33) | PDPK1GDACDK1CDK2 | |
| SCHEMBL13477906 | 0.81 | GDA (0.32) | PDPK1GDAPOLA1 | |
| SCHEMBL10047120 | 0.81 | L3MBTL1 (0.38) | PDPK1GAACCNB2CDK1CCNB1 | |
| SCHEMBL11876693 | 0.79 | XDH (0.39) | PDPK1CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL2730453 | 0.78 | ALOX15 (0.33) | PDPK1GDACDK1CDK2AURKB | |
| SCHEMBL16146951 | 0.78 | ADORA2A (0.41) | CDK1CDK2ALDH1A1MAPTPOLA1 | |
| SCHEMBL14938903 | 0.78 | CYP1A2 (0.39) | GDAALDH1A1AURKB | |
| SCHEMBL14110227 | 0.78 | XDH (0.38) | PDPK1CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL377762 | 0.78 | PDPK1 (0.33) | PDPK1CCNB2CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1936 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-8288354-B2 | Natural antisense and non-coding RNA transcripts as drug targets | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-10-16 | — | — | US | claimed |
| EP-1381694-A4 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS PHARMACEUTICALS INC (US) | 2006-08-16 | — | — | EP | claimed |
| US-6730484-B2 | POLYNUCLEOTIDE OR POLYPEPTIDE, AS WELL AS METHODS FOR DETERMINING WHETHER A PARTICULAR SITE IN A TARGET MOLECULE IS AT OR NEAR THE LIGAND BINDING SITE, ARE PROVIDED. LIGAND BINDING AFFINITIES CORRESPONDING TO BOTH THE TARGET MOLECULE | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-6730485-B2 | DETECTION OF BINDING DOMAIN IN POLYPEPTIDE; OBTAIN POLYPEPTIDE, INCUBATE WITH LIGAND, EXPOSE SPECTRUM ANALYSIS, DETECT BINDING DOMAIN IN PROTEIN | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| EP-1381694-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS Pharmaceuticals, Inc. (US) | 2004-01-21 | — | — | EP | claimed |
| US-6653067-B1 | Contacting with modified/unmodified test molecule and dissociating; comparing the unseparated complexes; mass spectrometry; use in drug discovery | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | claimed |
| US-20030165915-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | claimed |
| US-20030077630-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20030013113-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2002068691-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| EP-4746853-A1 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637682-B2 | Protein translational control | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2026-05-26 | — | — | US | disclosed |
| WO-2026107101-A2 | COMPOUNDS FOR TARGETING FERREDOXIN 2 (FDX2) IN FRIEDREICH ATAXIA (FRDA) | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-0590082-A4 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE. | ISIS PHARMACEUTICALS INC (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994008003-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE | ISIS PHARMACEUTICALS, INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0590082-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE | ISIS PHARMACEUTICALS, INC. (US) | 1994-04-06 | — | — | EP | disclosed |
| WO-1992022651-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE | ISIS PHARMACEUTICALS, INC. (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | NOS1 532/4885PDPK1 281/4885BTK 3989/4885 |
| US-12637682-B2 | Protein translational control | RNGTT, RNMT, METTL16 | NOS1 3436/4885PDPK1 3626/4885BTK 1560/4885 |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | DACH1, TNNT2, CDH1 | NOS1 1174/4885PDPK1 2204/4885BTK 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.